UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~October~~July 79, ~~2020~~2021

BIONOVATE TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

Nevada		333-188152		33-1229553
(State or other jurisdictionof incorporation)		(~~CommissionFile~~Commission File Number)		(IRS ~~EmployerIdentification~~Employer Identification No.)

Gewerbestrasse 10, Cham, Switzerland, 6330		06100
950 W Bannock St, Boise, Idaho		83702
(Address of principal executive offices)		(Zip Code)

Registrant s telephone number, including area code: (~~646~~280) ~~224~~231-~~1160~~1606

~~N/A~~Gewerbestrasse 10, Cham, Switzerland 6330

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~☐ Soliciting~~Indicate ~~material~~by ~~pursuant~~check tomark whether the registrant is an emerging growth company as defined in Rule ~~14a~~405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-122 ~~under~~of the Securities Exchange Act ~~(17~~of ~~CFR~~1934 ( 240.~~14a~~12b-122 of this chapter).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Item 15.0102 ~~Entry~~Departure ~~Into~~of ADirectors ~~Material~~or ~~Definitive~~Certain ~~Agreement~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~October~~July 79, ~~2020~~2021, Aleksander ~~Bionovate~~Vucak ~~Technologies~~resigned ~~Corp.~~as ~~(the~~a ~~“Company”)~~director ~~entered~~and ~~into~~as aan ~~Share~~officer ~~Exchange~~of ~~Agreement~~our (company. Mr. Vucak’s resignation was not the ~~“Share~~result ~~Exchange~~of ~~Agreement”)~~a ~~facilitated~~disagreement between ~~Evergreen~~Mr. ~~Solutions~~Vucak and our company on any matter relating to our company’s operations, ~~Ltd~~policies or practices. On July 9, 2021, Timothy Jones was appointed as a ~~private~~director ~~Company~~to ~~(“Evergreen”),~~replace Mr. Vucak and ~~Human~~he ~~Data~~was AGalso appointed President, aChief ~~private~~Executive ~~Switzerland~~Officer, ~~Company~~Chief ~~(“Human~~Financial ~~Data”).~~Officer, Secretary and Treasurer of our company.

~~Pursuant~~Mr. toJones, ~~the~~age ~~Share Exchange Agreement~~64, inbegan ~~exchange~~his ~~for~~career ~~the~~at ~~acquisition~~Bayer ofin ~~all~~1983 ofas ~~the~~a ~~outstanding~~sales ~~Company~~manager ~~shares~~after ~~which~~graduating ~~Evergreen~~in ~~owns,~~business toat ~~wit,~~a ~~54,270,000~~university ~~shares~~in (the ~~“Exchange~~United ~~Shares”),~~Kingdom. ~~the~~Mr. ~~Company~~Jones ~~will~~recently ~~receive~~retired ~~12,500~~from ~~shares~~his ofposition ~~Digital~~at ~~Diagnostics~~Bayer AGand ~~(“Digital”)~~is ~~owned~~now bypursuing ~~Human~~different ~~Data, which equates to 25% of the currently issued shares of Digital~~opportunities.

~~The~~There ~~Share~~are ~~Exchange~~no ~~Agreement~~family ~~contains~~relationship ~~customary~~between ~~representations~~Mr. ~~and~~Jones ~~warranties made by the Company, on the one hand,~~ and ~~Evergreen~~any ~~and~~director ~~Human~~or ~~Data~~executive onofficer ~~the other hand, made solely for the benefit~~ of ~~the~~our ~~other,~~company ~~which in certain cases are subject to specified exceptions~~ and ~~qualifications~~no ~~contained~~related inparty ~~the~~transactions ~~Share~~required ~~Exchange Agreement or in information provided pursuant~~ to ~~certain~~be ~~disclosure~~reported ~~schedules~~under toItem ~~the~~404(a) ~~Share~~of ~~Exchange~~Regulation ~~Agreement~~S-K.

~~Item 9.01 Financial Statements and Exhibits~~2

The foregoing descriptions of the Share Exchange Agreement do not purport to be complete and are subject to, and are qualified in their entirety by, the full text of this agreement, which is filed herewith as Exhibit 10.1, and incorporated herein by reference.SIGNATURES

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~SIGNATURES~~BIONOVATE TECHNOLOGIES CORP. /s/ Timothy Jones Timothy Jones President Date: July 14, 2021

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~3

BIONOVATE TECHNOLOGIES CORP. /s/ Aleksander Vucak Aleksander Vucak President Date: October 13, 2020

Filing Compare · Bionovate Technologies Corp.